Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Inovio Pharmaceuticals, Inc.    INO

INOVIO PHARMACEUTICALS, INC.

(INO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Inovio Pharmaceuticals, Inc. : Close to a key resistance level

share with twitter share with LinkedIn share with facebook
share via e-mail
05/22/2020 | 12:02pm EDT
long trade
Live
Entry price : 14.145$ | Target : 18.5$ | Stop-loss : 10.28$ | Potential : 30.79%
Inovio Pharmaceuticals, Inc. shares are closing in on important technical levels. The technical chart pattern suggests that the currently tested resistance will be broken and new upside potential arises while volatility is likely to increase. Investors could get ahead of this signal in order to benefit from a better risk/reward ratio.
Investors have an opportunity to buy the stock and target the $ 18.5.
Inovio Pharmaceuticals, Inc. : Inovio Pharmaceuticals, Inc. : Close to a key resistance level
Strengths
  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The tendency within the weekly time frame is positive above the technical support level at 5.35 USD

Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at USD 14.59.
  • The stock is close to a major daily resistance at USD 15.79, which should be gotten rid of so as to gain new appreciation potential.
  • Low profitability weakens the company.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart
Subsector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
INOVIO PHARMACEUTICALS, INC..326.67%2 226
LONZA GROUP41.79%38 304
IQVIA HOLDINGS INC.-7.13%27 289
SEATTLE GENETICS, INC.32.76%26 964
MODERNA, INC.195.04%26 829
CELLTRION, INC.18.51%23 163
INCYTE CORPORATION13.80%21 600
ALNYLAM PHARMACEUTICALS, IN..18.46%16 134
GALAPAGOS NV0.86%13 703
BIO-TECHNE CORPORATION18.74%10 183
QIAGEN N.V.27.99%9 812
More Results

David Meurisse
© MarketScreener.com 2020
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2020 38,3 M
EBIT 2020 -90,7 M
Net income 2020 -101 M
Debt 2020 -
Yield 2020 -
P/E ratio 2020 -21,0x
P/E ratio 2021 31,3x
Capi. / Sales2020 59,6x
Capi. / Sales2021 2,69x
Capitalization 2 286 M
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 14,00 $
Last Close Price 14,46 $
Spread / Highest target 93,6%
Spread / Average Target -3,18%
Spread / Lowest Target -65,4%
EPS Revisions
Managers
NameTitle
J. Joseph Kim President, Chief Executive Officer & Director
Simon X. Benito Chairman
Jacqueline E. Shea Chief Operating Officer & Executive Vice President
Peter D. Kies Chief Financial & Accounting Officer
Laurent M. Humeau Chief Scientific Officer